Effectiveness of Immune Checkpoint Inhibitors in the Treatment of Colon Adenocarcinoma

Abstract

Recently, immunotherapy has emerged as an innovative approach for the management of various cancers, particularly those in advanced stages. Among these novel interventions, immune checkpoint inhibitors have gained significant attention. Given the observed efficacy of these pharmaceutical agents in treating a range of solid tumors, such as metastatic melanoma, they present a promising therapeutic strategy for managing metastatic and advanced colorectal cancer (CRC). The high mortality and incidence rates associated with CRC, coupled with its substantial societal burden, underscore the critical need to assess the effectiveness and safety of this emerging treatment modality. The objective of this research is to evaluate the impact of diverse immune checkpoint inhibitors on the mortality and survival rates of patients with advanced CRC.